secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001108205-23-000048
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q1 net loss narrows to $11.6M; enrolls 9 patients for emavusertib; new CDO
--------------------------------------------------------------------------------

- Net loss $11.6M ($0.12/share) vs $16.1M ($0.18) YoY; revenue $2.3M, up from $2.1M.
- Enrolled 9 additional patients at 200mg BID for emavusertib; FDA partial clinical hold discussion expected in Q3 2023.
- Appointed Jonathan Zung, Ph.D. as Chief Development Officer effective May 1, 2023; previously CDO at Evelo.
- Cash and investments $71.8M as of Dec 31, 2022; cash runway expected into 2025.
- R&D expenses down to $9.1M from $11.4M; G&A down to $4.8M from $5.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820523000048/0001108205-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820523000048/cris-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001108205-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer